As a result, the initial, or first-line, treatment approach for patients with advanced NSCLC harboring KRAS mutations—including KRAS G12C—remains aligned with that for patients lacking actionable oncogenic drivers. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.